Childhood leukemia includes multiple subtypes, and risk and presentation vary by age and biology. In the United States, ALL makes up about 75% of childhood leukemia cases under age 15, while incidence peaks in high-income countries and is about 4.7 per 100,000 in Europe (2010–2014). Across pages on diagnosis and causes, you’ll see how factors like ionizing radiation exposure and Down syndrome shape risk, and how modern therapy affects outcomes by risk group and relapse.
Key Takeaways
- Bone pain in 25-40% of childhood ALL cases at presentation
- Anemia present in 80-90% of children with acute leukemia at diagnosis
- Leukocytosis >50,000/μL in 50% of ALL cases, often >100,000/μL
- In the United States, acute lymphoblastic leukemia (ALL) accounts for approximately 75% of all childhood leukemia cases diagnosed in children under 15 years old
- Globally, childhood leukemia incidence is highest in high-income countries with rates around 4-5 cases per 100,000 children aged 0-14 years
- In Europe, the age-standardized incidence rate of childhood leukemia (0-14 years) was 4.7 per 100,000 in 2010-2014 according to EUROCARE-5 data
- 5-year EFS 90% for standard-risk ALL age 1-9 WBC<50k no adverse genetics
- Overall survival for childhood ALL improved from 60% 1990s to 91% 2010s
- Infant ALL <12 months 5-year OS only 40-50% due to KMT2A rearrangements
- Ionizing radiation exposure before age 5 increases childhood leukemia risk by 2-3 fold per dose >100 mGy
- Down syndrome children have 10-20 times higher risk of acute megakaryoblastic leukemia (AMKL)
- Maternal alcohol consumption during pregnancy raises ALL risk by 1.5-2.0 times in offspring
- Multi-agent chemotherapy induction response rate 98-99% in standard-risk ALL
- Vincristine, prednisone, asparaginase, daunorubicin standard 4-drug induction for high-risk ALL
- Cranial radiation dose reduced to 12-18 Gy in average risk to minimize neurotoxicity
Childhood ALL is common, often presenting with anemia and high white counts, but survival now exceeds 90%.
Related reading
01 · Category
Diagnosis30 stats
01
Bone pain in 25-40% of childhood ALL cases at presentation
02
Anemia present in 80-90% of children with acute leukemia at diagnosis
03
Leukocytosis >50,000/μL in 50% of ALL cases, often >100,000/μL
04
Mediastinal mass on chest X-ray in 10-15% of T-cell ALL cases
05
CNS involvement at diagnosis in 3-5% of childhood ALL with blasts in CSF
06
Thrombocytopenia <100,000/μL in 70-80% of pediatric leukemia patients
07
Fatigue and pallor reported in 60% of cases as initial symptoms
08
Bone marrow blasts >20% required for WHO leukemia diagnosis in children
09
Lymphadenopathy in 50-60% of ALL presentations
10
Hyperleukocytosis >100,000/μL in 10-15% requiring urgent management
11
Splenomegaly in 60-70% of cases on physical exam
12
Flow cytometry detects aberrant immunophenotype in 95% of B-ALL
13
Fever present in 50-60% at diagnosis, often without infection
14
Hepatomegaly in 50% of childhood leukemia cases
15
Cytogenetic analysis shows t(12;21) ETV6-RUNX1 in 25% favorable ALL
16
Gum hypertrophy classic in 20-30% of AML M4/M5 subtypes
17
Bruising/petechiae in 40-50% due to low platelets
18
MRI for CNS leukemia detects subclinical disease in 20% post-treatment
19
Minimal residual disease (MRD) <0.01% by flow at day 15 predicts excellent outcome
20
Testicular involvement in 10-15% boys at diagnosis undetected clinically
21
Lactate dehydrogenase (LDH) >2x upper normal in 70% high-risk cases
22
RT-PCR for fusion transcripts sensitivity 1 in 10^5 cells for monitoring
23
Orbital proptosis in 5-10% AML with granulocytic sarcoma
24
Peripheral blasts in 90% of cases, key for initial suspicion
25
White cell count <10,000/μL in 20% ALL, prognostic good risk
26
Skin nodules in 10% infant leukemia MLL-rearranged
27
Bone X-rays show metaphyseal lucent bands in 50% ALL
28
Hypereosinophilia in 1-2% ALL with t(5;14) translocation
29
Urinalysis hematuria in 10% due to uric acid nephropathy early
30
PET-CT for extramedullary disease sensitivity 90% in AML
Interpretation
Diagnosis Interpretation
In the diagnosis of childhood leukemia, symptoms and labs are present in most patients, with anemia affecting 80–90% and thrombocytopenia under 100,000 per μL showing up in 70–80%, while bone pain occurs in 25–40% and CNS involvement is relatively uncommon at 3–5% at presentation.
02 · Category
Epidemiology30 stats
01
In the United States, acute lymphoblastic leukemia (ALL) accounts for approximately 75% of all childhood leukemia cases diagnosed in children under 15 years old
02
Globally, childhood leukemia incidence is highest in high-income countries with rates around 4-5 cases per 100,000 children aged 0-14 years
03
In Europe, the age-standardized incidence rate of childhood leukemia (0-14 years) was 4.7 per 100,000 in 2010-2014 according to EUROCARE-5 data
04
In the US, from 2016-2020, there were about 3,650 new cases of leukemia among children and adolescents aged 0-19 years per SEER data
05
Childhood acute myeloid leukemia (AML) represents 15-20% of all pediatric leukemias with an incidence of 0.7-1.0 per 100,000 children under 15
06
In low- and middle-income countries, childhood leukemia incidence is lower at 1-2 per 100,000 but mortality is higher due to access issues
07
Peak incidence of childhood ALL occurs between ages 2-5 years, comprising 60% of cases in that age group
08
In Australia, childhood leukemia incidence rate is 5.2 per 100,000 for ages 0-14 from 2012-2016
09
Hispanic children in the US have a 20% higher incidence of ALL compared to non-Hispanic whites at 4.6 vs 3.6 per 100,000
10
From 2001-2014, US childhood leukemia incidence increased slightly by 0.7% annually per CDC data
11
In Canada, annual incidence of childhood leukemia is 4.5 per 100,000 children under 15
12
Boys have a 15-20% higher incidence of childhood leukemia than girls globally
13
In India, childhood leukemia comprises 30% of childhood cancers with incidence rising to 3 per 100,000 urban areas
14
UK childhood leukemia incidence is 4.3 per 100,000 for 0-14 years per Cancer Research UK
15
White children in the US have higher ALL rates (3.6 per 100,000) than Black children (1.8 per 100,000)
16
Global burden: 98,000 new childhood leukemia cases annually per GLOBOCAN 2020
17
In Brazil, incidence of childhood ALL is 4.1 per 100,000 with regional variations up to 5.5 in south
18
Japan reports lower childhood leukemia incidence at 2.5 per 100,000 compared to Western countries
19
In South Africa, childhood leukemia incidence is 1.8 per 100,000 but underreported
20
US Native American children have ALL incidence of 3.9 per 100,000, higher than average
21
From 1990-2017, global age-standardized incidence of childhood leukemia increased by 0.5% yearly
22
In France, national registry shows 4.8 per 100,000 incidence for childhood leukemia 2000-2010
23
Asian/Pacific Islander US children have lowest ALL incidence at 2.3 per 100,000
24
Mexico reports 4.5 per 100,000 childhood leukemia incidence per national cancer registry
25
In Germany, childhood leukemia incidence stable at 4.1 per 100,000 over decades
26
Argentina has incidence of 3.9 per 100,000 for childhood ALL
27
Sweden reports 5.0 per 100,000 incidence with high registry completeness
28
In Egypt, childhood leukemia incidence is 2.1 per 100,000 but rising
29
New Zealand Maori children have 1.5 times higher leukemia incidence than Europeans
30
In 2020, Europe had 8,500 new childhood leukemia cases per ACCIS project
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, childhood leukemia follows a clear global pattern where incidence is about 4 to 5 per 100,000 children aged 0 to 14 in high income countries but only 1 to 2 per 100,000 in low and middle income countries, even though mortality is higher where access to care is limited.
03 · Category
Prognosis28 stats
01
5-year EFS 90% for standard-risk ALL age 1-9 WBC<50k no adverse genetics
02
Overall survival for childhood ALL improved from 60% 1990s to 91% 2010s
03
Infant ALL <12 months 5-year OS only 40-50% due to KMT2A rearrangements
04
T-cell ALL 5-year EFS 85% with modern Berlin-Frankfurt-Munster protocols
05
AML OS 60-70% in children vs 25% historical, per COG data
06
Hypodiploid ALL <44 chromosomes 5-year OS <40% poor prognosis
07
MRD negativity end-induction predicts 95% 5-year DFS in ALL
08
Ph+ ALL with imatinib 70% EFS vs 20% historical without TKI
09
Relapse within 3 years after 80% increased mortality risk
10
Down syndrome AML 5-year OS 80% better than non-DS
11
Late relapse >6 years from diagnosis 70-80% salvageable with chemo
12
ETV6::RUNX1 fusion 98% 5-year OS excellent prognosis group
13
CNS relapse alone 5-year OS 60-70% with HSCT
14
High hyperdiploid >50 chromosomes ALL 95% EFS
15
FLT3-ITD AML without NPM1 30% 5-year OS poor
16
Boys testicular relapse 80% overall survival post-salvage
17
KMT2A::AFF1 infant ALL 20-30% long-term survival
18
Post-HSCT relapse OS 20-30% dismal
19
Age 10-15 ALL EFS 75-80% intermediate risk
20
BM relapse OS 40-50% with intensified chemo/HSCT
21
iAMP21 ALL 5-year EFS 75% with intensified therapy
22
APL pediatric 5-year OS 95% with ATRA+chemo
23
WBC>100k at diagnosis halves EFS to 70% in ALL
24
TCR rearranged T-ALL 90% OS favorable subtype
25
CBFA2T3::GLIS2 fusion AML 10% 4-year OS very poor
26
Very late relapse >10 years 90% cure rate re-treatment
27
MRD >0.1% end consolidation EFS drops to 70%
28
Isolated extramedullary relapse 70-80% 5-year survival
Interpretation
Prognosis Interpretation
Overall prognosis for childhood leukemia has improved markedly, with childhood ALL rising from 60% overall survival in the 1990s to 91% in the 2010s, yet outcomes still vary sharply by subtype and risk such as infant ALL under 12 months with only 40 to 50% 5 year OS and hypodiploid ALL under 44 chromosomes with under 40% 5 year OS.
More related reading
04 · Category
Risk Factors30 stats
01
Ionizing radiation exposure before age 5 increases childhood leukemia risk by 2-3 fold per dose >100 mGy
02
Down syndrome children have 10-20 times higher risk of acute megakaryoblastic leukemia (AMKL)
03
Maternal alcohol consumption during pregnancy raises ALL risk by 1.5-2.0 times in offspring
04
Pesticide exposure in utero increases childhood leukemia risk by 2.4 odds ratio meta-analysis
05
High birth weight (>4kg) associated with 1.3 relative risk for childhood leukemia
06
Genetic syndromes like Fanconi anemia increase leukemia risk 500-1000 fold
07
Electromagnetic fields >0.4 μT from power lines raise risk by 1.7 OR
08
Twins have 2-4 times higher concordance rate for ALL than singletons
09
Benzene exposure at work for parents increases child leukemia risk by 1.8 RR
10
Noonan syndrome carries 200-fold increased risk of juvenile myelomonocytic leukemia (JMML)
11
Daycare attendance before age 1 reduces leukemia risk by 30-50% via infection hypothesis
12
Folate supplementation in pregnancy lowers neural tube defects but no significant leukemia risk change
13
TEL-AML1 fusion gene present in 25% of childhood ALL cases, strong risk marker
14
Maternal smoking during pregnancy increases AML risk by 1.2-1.5 OR
15
Li-Fraumeni syndrome TP53 mutations confer 100-fold leukemia risk
16
Older maternal age (>40) associated with 1.4 RR for ALL
17
Viral infections like EBV in infancy may protect against ALL by 40%
18
Paint exposure in home during pregnancy raises risk 2.0 OR for AML
19
Neurofibromatosis type 1 increases JMML risk 30-50 fold
20
Traffic-related air pollution PM2.5 exposure increases risk by 1.3 per 10μg/m3
21
Cesarean delivery associated with 10-20% higher ALL risk vs vaginal birth
22
Ataxia-telangiectasia gene mutations raise leukemia risk 70-fold
23
Parental preconception pesticide use OR 1.9 for child leukemia
24
Short birth interval (<12 months) increases risk by 1.5 RR
25
Swimming pool disinfection byproducts exposure OR 1.6 for leukemia
26
Kostmann syndrome neutropenia leads to 20% risk of MDS/AML transformation
27
Obesity in adolescence prior to diagnosis linked to poorer outcomes but not incidence
28
Residential proximity to nuclear facilities no significant risk increase per meta-analysis
29
Common ALL antigen (CALLA) positive cases 80-90% but not causal risk
30
In utero solvent exposure OR 2.6 for childhood leukemia
Interpretation
Risk Factors Interpretation
In the risk factors category, several exposures and conditions show large, dose or condition linked jumps in childhood leukemia risk, with ionizing radiation before age 5 raising risk by 2 to 3 fold per dose over 100 mGy and genetic syndromes like Fanconi anemia increasing risk by about 500 to 1000 fold.
05 · Category
Treatment25 stats
01
Multi-agent chemotherapy induction response rate 98-99% in standard-risk ALL
02
Vincristine, prednisone, asparaginase, daunorubicin standard 4-drug induction for high-risk ALL
03
Cranial radiation dose reduced to 12-18 Gy in average risk to minimize neurotoxicity
04
HSCT cure rate 50-60% for relapsed ALL in second remission
05
Blinatumomab achieves 44% complete remission in relapsed/refractory B-ALL
06
CAR-T therapy tisagenlecleucel 81% remission rate in refractory B-ALL phase 2 trial
07
Maintenance therapy with 6-MP and MTX for 2-3 years post-induction standard
08
Cytarabine + anthracycline induction for AML achieves 80-90% CR
09
Nelarabine 30-50% response in T-ALL relapsed cases
10
Allogeneic HSCT recommended for AML with FLT3-ITD high allelic ratio
11
Inotuzumab ozogamicin 81% CR/CRi in relapsed CD22+ ALL adults but 70% pediatric
12
Total therapy duration 2 years girls, 3 years boys in COG protocols ALL
13
Gemtuzumab ozogamicin adds 15% EFS benefit in CD33+ pediatric AML
14
Interim maintenance with CAP (CTX, MTX, ASP) pulses every 12 weeks
15
Chimeric antigen receptor T-cell targeting CD19 FDA approved 2017 for refractory ALL
16
Delayed intensification phase improves EFS by 10-15% in high-risk ALL
17
Liposomal daunorubicin reduces cardiotoxicity while maintaining efficacy
18
Prophylactic IT MTX 12-16 doses prevents CNS relapse 95% efficacy
19
Clofarabine 30% CR2 rate in multiply relapsed pediatric ALL/AML
20
Augmented BFM protocol for infants MLL+ uses dose-intensive therapy
21
Rasburicase prevents TLS in 93% high-risk hyperuricemia cases
22
Pegylated asparaginase extends half-life to 14 days vs 0.6 native
23
ATRA + arsenic trioxide for APL achieves 97% CR in children
24
Weekly vs daily MTX pulses compared in maintenance, equivalent EFS
25
Fludarabine + cytarabine salvage 50% response pre-HSCT
Interpretation
Treatment Interpretation
Treatment outcomes for childhood leukemia are strong but increasingly tailored, with induction response reaching 98 to 99% in standard-risk ALL while newer targeted approaches like blinatumomab and CAR-T therapy produce 44% and 81% remission rates in relapsed or refractory B-ALL.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Childhood Leukemia Statistics. Gitnux. https://gitnux.org/childhood-leukemia-statistics
MLA
Megan Gallagher. "Childhood Leukemia Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/childhood-leukemia-statistics.
Chicago
Megan Gallagher. 2026. "Childhood Leukemia Statistics." Gitnux. https://gitnux.org/childhood-leukemia-statistics.
Sources & references
15 datasets cited across this report · attribution is report-level